PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28028949-0 2016 Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia. Clarithromycin 0-14 interleukin 6 Homo sapiens 25-29 28861755-0 2020 Clarithromycin decreases rhinovirus replication and cytokine production in nasal epithelial cells from subjects with bronchial asthma: effects on IL-6, IL-8 and IL-33. Clarithromycin 0-14 interleukin 6 Homo sapiens 146-150 28028949-9 2016 Clarithromycin treatment resulted in a significantly lower mean value of serum IL-6 responders than non-responders. Clarithromycin 0-14 interleukin 6 Homo sapiens 79-83 28028949-10 2016 CONCLUSIONS: In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-beta, and of rations, and of the BAL-f concentration of IL-6. Clarithromycin 42-56 interleukin 6 Homo sapiens 124-128 28028949-10 2016 CONCLUSIONS: In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-beta, and of rations, and of the BAL-f concentration of IL-6. Clarithromycin 42-56 interleukin 6 Homo sapiens 199-203 23199585-7 2013 CAM and AZM induced a dose-dependent suppression of spontaneous TNF-alpha, sTNFR2, IL-6, IL-8 and CCL18 production (p<0.05). Clarithromycin 0-3 interleukin 6 Homo sapiens 83-87 26987326-3 2016 The present study was performed to assess the correlation between concentrations of IL-1beta, IL-6, IL-8, and TGF-beta1 in the serum with response to clarithromycin (CAM) treatment in patients with COP. Clarithromycin 150-164 interleukin 6 Homo sapiens 94-98 26987326-9 2016 We conclude that IL-6, IL-8, and TGF-beta1 may play a role in the pathogenesis of COP, as their decreased concentrations were associated with a positive response to CAM treatment. Clarithromycin 165-168 interleukin 6 Homo sapiens 17-21 25749777-10 2015 In addition, clarithromycin significantly alleviated IL-6-induced FoxA2 suppression and decreased MUC5AC expression in vitro (P<0.05). Clarithromycin 13-27 interleukin 6 Homo sapiens 53-57 23199585-10 2013 CAM also inhibited the LPS-stimulated TNF-alpha, IL-1beta, IL-6 and IL-10 production. Clarithromycin 0-3 interleukin 6 Homo sapiens 59-63 11786660-8 2001 After 3 months of CAM treatment, serum levels of IL-6 significantly decreased. Clarithromycin 18-21 interleukin 6 Homo sapiens 49-53 22564837-9 2012 The release of TNF-alpha, IL-6, and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) by circulating monocytes after stimulation was greater in the clarithromycin group than in the placebo group. Clarithromycin 165-179 interleukin 6 Homo sapiens 26-30 22761540-3 2012 Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES). Clarithromycin 0-14 interleukin 6 Homo sapiens 146-159 22761540-3 2012 Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES). Clarithromycin 16-19 interleukin 6 Homo sapiens 146-159 16387930-1 2006 Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection. Clarithromycin 0-14 interleukin 6 Homo sapiens 130-148 16387930-1 2006 Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection. Clarithromycin 16-18 interleukin 6 Homo sapiens 130-148 15078004-0 2004 Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia. Clarithromycin 28-42 interleukin 6 Homo sapiens 62-66 15078004-7 2004 Clarithromycin significantly decreased plasma levels of IL-6 and significantly increased those of IFNgamma and IL-10 at the 3rd and 7th day in comparison to basal levels. Clarithromycin 0-14 interleukin 6 Homo sapiens 56-60 22559798-5 2012 Clarithromycin treatment decreased the levels of eosinophilic cationic protein only in non-allergic patients (p < 0.05), and decreased the level of interleukin 6 only in allergic patients (p < 0.05). Clarithromycin 0-14 interleukin 6 Homo sapiens 151-164 21315154-4 2011 Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release. Clarithromycin 51-65 interleukin 6 Homo sapiens 152-156 11786660-11 2001 Furthermore, CAM-treated patients whose serum IL-6 levels were decreased after 3 months of treatment survived longer: there was a statistically significant correlation between the decrease in serum IL-6 and survival time. Clarithromycin 13-16 interleukin 6 Homo sapiens 46-50 11786660-11 2001 Furthermore, CAM-treated patients whose serum IL-6 levels were decreased after 3 months of treatment survived longer: there was a statistically significant correlation between the decrease in serum IL-6 and survival time. Clarithromycin 13-16 interleukin 6 Homo sapiens 198-202 10221415-5 1999 The results with IL-6 and TNF-alpha in the clarithromycin studies were most striking. Clarithromycin 43-57 interleukin 6 Homo sapiens 17-21 7763252-2 1995 Among those tested, erythromycin (EM) and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-6 at the therapeutic and non-cytotoxic concentration (10(-6)M). Clarithromycin 42-56 interleukin 6 Homo sapiens 121-125 34363189-7 2021 Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of production of interferon-gamma and decrease of production of interleukin-6 by mononuclear cells; and by suppression of SARS-CoV-2 viral load. Clarithromycin 0-14 interleukin 6 Homo sapiens 117-135 34363189-7 2021 Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of production of interferon-gamma and decrease of production of interleukin-6 by mononuclear cells; and by suppression of SARS-CoV-2 viral load. Clarithromycin 0-14 interleukin 6 Homo sapiens 213-226 35440370-6 2022 The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038). Clarithromycin 31-45 interleukin 6 Homo sapiens 78-82 34636179-11 2021 Interleukin-6 (IL-6) and IL-8 production by stimulated ECs were unaltered by incubation with macrolides, whereas Clarithromycin exposure significantly decreased IL-6 gene expression. Clarithromycin 113-127 interleukin 6 Homo sapiens 161-165